Thetis Pharmaceuticals LLC and Harvard Medical School have presented data on the stable salt chelate of Resolvin E1, TP-317, for the potential treatment of immune checkpoint inhibitor (ICI)-resistant ...
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial The WSG TP-II trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results